Search

This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.

With President-elect Trump returning to the White House and Republicans controlling Congress, significant changes to the Medicaid expansion are expected. This data note provides key facts on the Medicaid expansion, highlighting the financial and coverage impacts of any changes across states that voted for President-elect Trump and those that voted for Vice President Harris.

Juliette Cubanski is deputy director of the Program on Medicare Policy at KFF, where she has been conducting research and analysis on Medicare policy issues since 2004. Dr. Cubanski leads work on Medicare prescription drug coverage and related policy issues, including the examination of trends in the Medicare Part D…

It’s quite likely that one of these popular anti-obesity medications will be selected for negotiation in the next round of Medicare’s relatively new drug price negotiation program.

This brief provides background on gender affirming care and state bans, explains the legal challenge to the Tennessee law, and explores the potential Supreme Court ruling and impact on access across the country.

This topic page houses KFF resources that are relevant to policy debates in the 2024 elections, including those about abortion, the Affordable Care Act, and Medicare.

Dual eligibles, Dually eligible, Dually enrolled, duals

Dual eligibles, Dually eligible, Dually enrolled, duals